CD274 and neoplasm: While selecting patients that will benefit from immunotherapies remains a challenge, PD-L1 expression by IHC still hold some value, as tumor overexpressing PD-L1 frequently demonstrate to have improved outcomes to anti-PD1 therapies; however, the response to this therapy in patients with low PD-L1 levels demonstrate that it may not be an exclusive predictive biomarker to select patients for these therapeutic regimens [38].